# Scott Rocklage

> Scott Rocklage is a Series B investor at 5AM Ventures backing Biotechnology and Health Care. See 14 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [5AM Ventures](https://shizune.co/investors/profile/5am-ventures)
- Location: Menlo Park, United States
- Total investments: 14
- Last investment: Nov 2023
- Lead investor: 29%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/scott-rocklage-66aa7a12a
- X (Twitter): https://www.twitter.com/wordpressdotcom
- Website: https://scottrocklage.wordpress.com/

Scott Rocklage is a Series B investor at 5AM Ventures in Menlo Park focused on Biotechnology and Health Care. Scott Michael Rocklage is based out of Palm Beach Gardens, Florida and currently works as a Founding Partner for 5AM Ventures. Scott previously worked at Cubist Pharmaceuticals as a Chairman and CEO. Scott Michael Rocklage attended the University of California Berkeley.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 8 | 57% |
| Health Care | 6 | 43% |
| Therapeutics | 3 | 21% |
| Pharmaceutical | 3 | 21% |
| Medical | 2 | 14% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 6 | 43% |
| Series A | 4 | 29% |
| Series C | 2 | 14% |
| Series D | 1 | 7% |
| Post-IPO Equity | 1 | 7% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 5 | 36% |
| Sweden | 1 | 7% |
| Switzerland | 1 | 7% |
| United Kingdom | 1 | 7% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Nouscom | Nouscom are a well established team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos, and are veterans in the field of oncolytic and genetic vaccines. The company is headquartered in Basel, Switzerland and has operations in Rome, Italy.The NousCom team is lead by experiencedenterpreneurs that worked together for many years in previous successful enterprises, such as Okairos, under the leadership of Prof. Riccardo Cortese, who conceived the ideas behind those companies. | $73.4M | Series C | Nov 14, 2023 |  |
| Expansion Therapeutics | Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases. | $80M | Series B | Sep 29, 2021 |  |
| NodThera | NodThera is a Cambridge (UK) headquartered biotech engaged in innate immune/ inflammasome research. Their leading project is focused on developing inhibitors of the NLRP3 inflammasome for the treatment of inflammatory and neuroinflammatory diseases. | $55M | Series B | Jun 03, 2020 |  |
| NodThera | NodThera is a Cambridge (UK) headquartered biotech engaged in innate immune/ inflammasome research. Their leading project is focused on developing inhibitors of the NLRP3 inflammasome for the treatment of inflammatory and neuroinflammatory diseases. | $40M | Series A | Jun 25, 2018 |  |
| Expansion Therapeutics | Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases. | $55.3M | Series A | Jan 03, 2018 |  |
| Nouscom | Nouscom are a well established team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos, and are veterans in the field of oncolytic and genetic vaccines. The company is headquartered in Basel, Switzerland and has operations in Rome, Italy.The NousCom team is lead by experiencedenterpreneurs that worked together for many years in previous successful enterprises, such as Okairos, under the leadership of Prof. Riccardo Cortese, who conceived the ideas behind those companies. | $44.6M | Series B | Nov 06, 2017 |  |
| Aprea | Aprea is a Swedish biotech company focusing on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53. The Company's lead program, APR-246, is a first-in-class small molecule drug candidate in clinical development. Aprea's main shareholder is KDev Investments AB, an investment vehicleowned by Karolinska Development AB (Nasdaq Stockholm: KDEV) and Rosetta Capital Ltd. Other shareholders include Östersjöstiftelsen, Praktikerinvest, and KCIF Co-Investment Fund KB. | $50.5M | Series B | Mar 09, 2016 |  |
| Pulmatrix | Pulmatrix is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is initially focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaledanti-fungal for patients with ABPA, and PUR1800, a narrow spectrum kinase inhibitor in lung cancer. Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by achieving optimal local drug concentrations and reducing systemic side effects to improve patient outcomes. | $10M | Post-IPO Equity | Jun 16, 2015 |  |
| Novira Therapeutics | Novira Therapeutics is an antiviral drug discovery company that is focused on the discovery of first-in-class antiviral therapeutics for the treatment of chronic HBV and HIV infections, two global diseases with high levels of unmet need. Novira’s oral drugs target the capsid of the virus, and offer a promising treatment option both as monotherapyand in combination with current standards of care. The company’s antivirals potentially address limitations in treating chronic HBV infection, a disease for which the only class of oral drugs available, polymerase inhibitors, are rarely curative and often require lifelong treatment, as well as in chronic HIV infection, a disease for which the continued ability of the virus to mutate inevitably leads to drug-resistant viral strains. Each of these limitations to the standard of care can potentially be addressed by capsid inhibitors which feature a new mechanism of action. | $25M | Series A | Mar 24, 2013 |  |
| Achaogen | Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. The company's most advanced drug candidate, ACHN-490, has demonstrated a positive safety and dosing profile in Phase 1 clinical testing and displayed broad spectrumefficacy in preclinical studies against systemic infections caused by multi-drug resistant (MDR) Gram-negative bacteria (e.g., E. coli, K. pneumoniae, and P. aeruginosa) and MRSA. In addition, the company is pursuing preclinical programs in several other areas of interest to combat the global emergence of bacterial resistance. | $18.9M | Series D | Mar 22, 2013 |  |

10 of 14 investments shown.

## Co-investors
- [Versant Ventures](https://shizune.co/investors/profile/versant-ventures) — VC Fund, 7 deals together
- [Domain Associates](https://shizune.co/investors/profile/domain-associates) — VC Fund, 3 deals together
- [Novartis Venture Fund](https://shizune.co/investors/profile/novartis-venture-fund) — VC Fund, 3 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 3 deals together
- [Sanofi Ventures](https://shizune.co/investors/profile/sanofi-genzyme-bioventures) — VC Fund, 3 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 2 deals together

## About 5AM Ventures

VC Fund · Menlo Park, United States

5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries. 5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.

5 contacts available at 5AM Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Kush Parmar | Managing Partner | https://shizune.co/investors/profile/kush-parmar |
| Scott Rocklage | Founding Partner | https://shizune.co/investors/profile/scott-m-rocklage |
| Andrew Schwab | Managing Partner | https://shizune.co/investors/profile/andrew-schwab |
| Deborah Palestrant | Partner | https://shizune.co/investors/profile/deborah-palestrant |
| James W. Young | Venture Partner | https://shizune.co/investors/profile/james-w-young |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Scott Rocklage invest in?

Scott Rocklage invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Scott Rocklage last invest?

The most recent investment recorded for Scott Rocklage closed in Nov 2023. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co